We are live on ! Find out more
ORPH

Orphazyme A/S
ORPH

Delisted

ORPH was delisted on the 30th of March, 2022.

Back to rankings

9 hedge funds and large institutions have $2.42M invested in Orphazyme A/S in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 4 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more funds holding

Funds holding: 5 → 9 (+4)

31% more capital invested

Capital invested by funds: $1.84M → $2.42M (+$579K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 4

Holders
9
Holders Change
+4
Holders Change %
+80%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
–
Reduced
4
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$1.64M
2
PHK
Point72 Hong Kong
Hong Kong
+$59.3K
3
CSS
Cubist Systematic Strategies
Connecticut
+$6.03K
4
TRCT
Tower Research Capital (TRC)
New York
+$640

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$141K
2
CCM
CAAS Capital Management
New York
-$59.6K
3
Bank of America
Bank of America
North Carolina
-$49.3K
4
UBS Group
UBS Group
Switzerland
-$24.8K

ORPH Hedge Fund Activity: Q1 2021 in Review

9 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Orphazyme A/S (ORPH) for Q1 2021, worth a combined $2.42M — up 31% from $1.84M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new ORPH positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 4 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $1.64M. The largest seller was Millennium Management, cutting an estimated $141K.

  • 9 institutional investors held Orphazyme A/S (ORPH) as of Q1 2021, up from 5 in Q4 2020.
  • Funds reported $2.42M of Orphazyme A/S stock for Q1 2021, up 31% quarter-over-quarter.
  • 4 funds opened new Orphazyme A/S positions in Q1 2021 and 0 closed out, a net change of +4 holders.
  • The largest Orphazyme A/S buyer in Q1 2021 was Point72 Asset Management, an estimated $1.64M added.
  • The largest Orphazyme A/S seller in Q1 2021 was Millennium Management, an estimated $141K sold.

Based on aggregated 13F filings for Q1 2021.